Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

BACKGROUND: The global, randomized, phase 3 REACH-2 study (ClinicalTrials.gov identifier: NCT02435433) found significantly longer overall survival (OS) for second-line ramucirumab versus placebo (hazard ratio [HR]: 0.710, 95% confidence interval [CI] 0.531–0.949, P = 0.0199) in patients with advance...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Gastroenterol
Asıl Yazarlar: Kudo, Masatoshi, Okusaka, Takuji, Motomura, Kenta, Ohno, Izumi, Morimoto, Manabu, Seo, Satoru, Wada, Yoshiyuki, Sato, Shinpei, Yamashita, Tatsuya, Furukawa, Masayuki, Aramaki, Takeshi, Nadano, Seijin, Ohkawa, Kazuyoshi, Fujii, Hirofumi, Kudo, Toshihiro, Furuse, Junji, Takai, Hiroki, Homma, Gosuke, Yoshikawa, Reigetsu, Zhu, Andrew X.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Singapore 2020
Konular:
Original Article—Liver, Pancreas, and Biliary Tract
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7242235/
https://ncbi.nlm.nih.gov/pubmed/32107609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-020-01668-w
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller